| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,823 |
2,420 |
$100K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,522 |
2,229 |
$75K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
633 |
614 |
$48K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
778 |
749 |
$42K |
| 99215 |
Prolong outpt/office vis |
701 |
645 |
$25K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
200 |
194 |
$25K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
657 |
582 |
$25K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,044 |
1,726 |
$20K |
| 99000 |
|
366 |
342 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
194 |
171 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
636 |
537 |
$2K |
| 81002 |
|
535 |
487 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,129 |
1,046 |
$947.26 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
62 |
59 |
$575.46 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
202 |
183 |
$371.75 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
26 |
24 |
$330.61 |
| J2300 |
Injection, nalbuphine hydrochloride, per 10 mg |
20 |
12 |
$94.17 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
61 |
53 |
$0.00 |